Substance
ID:670
Names and Identifiers
IUPAC name
gadolinium(3+) ion bis((2R,3R,4R,5S)-6-(methylamino)hexane-1,2,3,4,5-pentol) 2-[bis({2-[(carboxylatomethyl)(carboxymethyl)amino]ethyl})amino]acetate
Brand Name
Gadopentetic Acid Dimeglumine SaltMagnevist
Synonyms
Gadopentetate dimeglumine
IUPAC Traditional name
gadolinium(3+) H2dtpa bis(N-methyl-D(-)-glucamine)
Properties
No Data Available
Click here to submit data
Molecule Details
Drug Groups
approved
Description
A complex of gadolinium with a chelating agent, diethylenetriamine penta-acetic acid (DTPA see pentetic acid), that is given to enhance the image in cranial and spinal MRIs. (From Martindale, The Extra Pharmacopoeia, 30th ed, p706)
Indication
For use with magnetic resonance imaging (MRI) in adults, and pediatric patients (2 years of age and older) to visualize lesions with abnormal vascularity in the brain (intracranial lesions), spine and associated tissues as well as lesions with abnormal vascularity in the head and neck. Also used to facilitate the visualization of lesions with abnormal vascularity in the body (excluding the heart).
Affected Organisms
Humans and other mammals
Biotransformation
No detectable biotransformation or decomposition.
Half Life
Distribution half life 12 minutes, elimination half 100 minutes
Elimination
Gadopentetate is exclusively eliminated in the urine with 83 ± 14% (mean ± SD) of the dose excreted within 6 hours and 91 ± 13% (mean ± SD) by 24 hours, post-injection.
Distribution
* 266 ± 43 mL/kg
Clearance
* 1.94 +/- 0.28 mL/min/kg [Normal subjects]
External Links
Molecular Spectra
No Data Available
Click here to submit data
References
No Data Available
Click here to submit data